• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?

作者信息

O'Shea John G

机构信息

Newcastle Eye Centre, Newcastle, NSW, Australia and School of Medicine and Public Health, University of Newcastle, NSW, Australia.

出版信息

Clin Exp Optom. 2012 Sep;95(5):541-3. doi: 10.1111/j.1444-0938.2012.00736.x. Epub 2012 Jun 5.

DOI:10.1111/j.1444-0938.2012.00736.x
PMID:22672003
Abstract
摘要

相似文献

1
Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?关于在药品福利计划中用贝伐单抗替代雷珠单抗的回应：现有证据将我们置于何处？
Clin Exp Optom. 2012 Sep;95(5):541-3. doi: 10.1111/j.1444-0938.2012.00736.x. Epub 2012 Jun 5.
2
Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?在药品福利计划中用贝伐单抗替代雷珠单抗：现有证据将我们置于何处？
Clin Exp Optom. 2012 Sep;95(5):538-40. doi: 10.1111/j.1444-0938.2012.00735.x. Epub 2012 May 24.
3
[Age-related visual loss].[与年龄相关的视力丧失]
MMW Fortschr Med. 2013 Feb 7;155(2):36-7. doi: 10.1007/s15006-013-0107-x.
4
Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?遗传因素能否预测年龄相关性黄斑变性患者对抗血管内皮生长因子治疗的反应？
Can J Ophthalmol. 2011 Dec;46(6):549-51. doi: 10.1016/j.jcjo.2011.09.022.
5
Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.用于黄斑变性的药物、价格歧视以及医疗保险避免多支付费用的责任。
JAMA. 2014 Jul 2;312(1):23-4. doi: 10.1001/jama.2014.6672.
6
Bevacizumab in ophthalmology: the controversy moves forward.贝伐单抗在眼科领域的应用：争议仍在继续。
Clin Exp Ophthalmol. 2010 May;38(4):333-4. doi: 10.1111/j.1442-9071.2010.02300.x.
7
Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
BMJ. 2012 May 9;344:e3275. doi: 10.1136/bmj.e3275.
8
New treatments for age-related macular degeneration.年龄相关性黄斑变性的新疗法。
Lancet. 2007 Oct 27;370(9597):1479-80; author reply 1480. doi: 10.1016/S0140-6736(07)61625-0.
9
Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.血管内皮生长因子抑制剂治疗黄斑变性后的卒中发生率：时间序列分析。
Ophthalmology. 2012 Aug;119(8):1604-8. doi: 10.1016/j.ophtha.2012.05.028. Epub 2012 Jun 19.
10
Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.贝伐单抗与雷珠单抗治疗新生血管性年龄相关性黄斑变性的成本-效用分析：基于马尔可夫模型。
J Eval Clin Pract. 2012 Apr;18(2):247-55. doi: 10.1111/j.1365-2753.2010.01546.x. Epub 2010 Sep 16.

引用本文的文献

1
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients.贝伐单抗与雷珠单抗治疗中国患者新生血管性年龄相关性黄斑变性的对比
Int J Ophthalmol. 2013 Apr 18;6(2):169-73. doi: 10.3980/j.issn.2222-3959.2013.02.12. Print 2013.